India Approves Novo Nordisk's Wegovy for Fatty Liver Disease Treatment

India's drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has granted approval for Novo Nordisk's Wegovy (semaglutide) 2.4 mg injection as a treatment for metabolic dysfunction‑associated steatohepatitis (MASH), a serious form of non‑cirrhotic fatty liver disease. The approval makes Wegovy the first GLP‑1 receptor agonist approved worldwide and in India for MASH in adults with moderate to advanced liver fibrosis, to be used alongside a reduced‑calorie diet and increased physical activity.

Novo Nordisk highlighted that roughly two‑thirds of the Indian population are affected by fatty liver disease, creating a large potential patient pool. The company noted the limited treatment options currently available and the heightened risk of liver complications and cardiovascular disease among patients with MASH. Wegovy is already approved in India for chronic weight management and type 2 diabetes, and the new indication expands its therapeutic use.

The approval positions Novo Nordisk to compete with other obesity and diabetes drugs in the Indian market, where local manufacturers have introduced generic semaglutide products. Early sales data show the company sold about 76,000 Wegovy units in the first six months of 2026.